Update on the Role of Immunotherapy in the Management of Kidney Cancer

Abstract

Get full access to this article

View all access options for this article.

References

Parker

S.L.

, Tong

, Bolden

Cancer statistics, 1996. CA Cancer J Clin. 1996; 46: 5–27.

Stenzl

, deKernion

J.B.

Pathology, biology, and clinical staging of renal cell carcinoma. Semin Oncol. 1989; 16(suppl 1): 3–11.

Yagoda

Chemotherapy of renal cell carcinoma: 1983–1989. Semin Urol. 1989; 7: 199–206.

Montie

J.E.

, Stewart

B.H.

, Straffon

R.A.

The role of adjunctive nephrectomy in patients with metastatic renal cell carcinoma. J Urol. 1977; 117: 272–275.

Quesada

J.R.

, Rios

, Swanson

Antitumor activity of recombinant-derived interferon alpha in metastatic renal cell carcinoma. J Clin Oncol. 1985; 3: 1522–1528.

Balkwill

F.R.

, Moodie

E.M.

Positive interactions between human interferon and cyclophosphamide or Adriamycin in a human tumor model system. Cancer Res. 1984; 44: 904–908.

Figlin

R.A.

, deKernion

J.B.

, Mukamel

Recombinant interferon alfa-2a in metastatic renal cell carcinoma: assessment of antitumor activity and anti-interferon antibody formation. J Clin Oncol. 1988; 6: 1604–1610.

Sertoli

M.R.

, Brunetti

, Ardizzoni

Recombinant alpha-2a interferon plus vinblastine in the treatment of metastatic renal cell carcinoma. Am J Clin Oncol. 1989; 12: 43–45.

Aulitzky

, Gastl

, Aulitzky

W.E.

Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma. J Clin Oncol. 1989; 7: 1875–1884.

10.

Ernstoff

M.S.

, Nair

, Bahnson

R.R.

A phase IA trial of sequential administration recombinant DNA-produced interferons: combination recombinant interferon gamma and recombinant interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol. 1990; 8: 1637–1649.

11.

Mule

J.J.

, Shu

, Schwarz

S.L.

Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science. 1984; 225: 1487–1489.

12.

Rosenberg

S.A.

, Lotze

M.T.

, Yang

J.C.

Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989; 210: 474–485.

13.

Rosenberg

S.A.

Adoptive cellular therapy in patients with advanced cancer: an update. Biol Ther Cancer Updates. 1991; 1: 1–15.

14.

Rosenberg

S.A.

, Lotze

M.T.

, Yang

J.C.

Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst. 1993; 85: 622–632.

15.

Robertson

C.N.

, Linehan

W.M.

, Pass

H.I.

Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol. 1990; 144: 614–618.

16.

Spencer

W.F.

, Linehan

W.M.

, Walther

M.M.

Immunotherapy with interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer with in situ primary cancers: a pilot study. J Urol. 1992; 147: 24–30.

17.

Siegel

J.P.

, Puri

R.K.

Interleukin-2 toxicity. J Clin Oncol. 1991; 9: 694–704.

18.

Sosman

J.A.

, Kohler

P.C.

, Hank

Repetitive weekly cycles of recombinant human interleukin-2: responses of renal carcinoma with acceptable toxicity. J Natl Cancer Inst. 1988; 80: 60–63.

19.

Whitehead

R.P.

, Wolf

M.K.

, Solanki

D.L.

A phase II trial of continuous-infusion recombinant interleukin-2 in patients with advanced renal cell carcinoma: a Southwest Oncology Group study. J Immunother. 1995; 18: 104–114.

20.

Whitehead

R.P.

, Ward

, Hemingway

Subcutaneous recombinant interleukin-2 in a dose escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res. 1990; 50: 6708–6715.

21.

Angevin

, Valteau-Couanet

, Farace

Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer. J Immunother. 1995; 18: 188–195.

22.

Huland

, Huland

, Heinzer

Interleukin-2 by inhalation: local therapy for metastatic renal cell carcinoma. J Urol. 1992; 147: 344–348.

23.

Yang

J.C.

, Topalian

S.L.

, Parkinson

Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol. 1994; 12: 1572–1576.

24.

Rosenberg

S.A.

, Speiss

, Lafreniere

A new approach to the adoptive immuno-therapy of cancer with tumor-infiltrating lymphocytes. Science. 1986; 233: 1318–1321.

25.

Rosenberg

S.A.

, Packard

B.S.

, Arebersold

P.M.

Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma: a preliminary report. N Engl J Med. 1988; 319: 1676–1680.

26.

Belldegrun

, Pierce

, Kaboo

Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma. J Urol. 1993; 150: 1384–1390.

27.

Kirchner

de Riese W, Allhoff E, et al. Immunotherapy of advanced renal cell cancer using subcutaneous recombinant interleukin-2 and interferon-alpha. World J Urol. 1991; 9: 219–222.

28.

Atzpodien

, Poliwoda

, Kirchner

Alpha-interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients. Semin Oncol. 1991; 18(suppl 7): 108–112.

29.

Figlin

R.A.

, Belldegrun

, Maldawer

Concomitant administration of recombinant human interleukin-2 and recombinant interferon alpha-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol. 1992; 10: 414–421.

30.

Lummen

, Goepel

, Mollhoff

Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. J Urol. 1996; 155: 455–458.

31.

Hänninen

L.E.

, Kirchner

, Atzpodien

Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients. J Urol. 1996; 155: 19–25.

32.

Giditz

B.J.

, Dolan

, Pierce

Fluoropyridines plus interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma: the UCLA Kidney Cancer Program. Proc Annu Meet Am Soc Clin Oncol. 1996; 15: A630.

33.

Bukowski

R.M.

, Budd

G.T.

, Peereboom

Phase I/II trial of simultaneously administered IL-2/HuIFN-alpha-2a and 5-FU in patients with metastatic renal cell carcinoma (RC). Proc Annu Meet Am Soc Clin Oncol. 1996; 15: A691.

34.

Dutcher

, Logan

, Gordon

5-FU and subcutaneous (SC) interleukin (IL-2) plus Intron (IFN) in metastatic renal cancer (RCC) patients (PTS): a CWG Study. Proc Annu Meet Am Soc Clin Oncol. 1996; 15: A725.

35.

Rosenberg

S.A.

, Aebersold

, Cornetta

Gene transfer into humans: immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med. 1990; 323: 570–578.

36.

Belldegrun

, Tso

C.L.

, Sakata

Human renal carcinoma line transfected with interleukin-2 and/or interferon alpha genes(s): implications for live cancer vaccines. J Natl Cancer Inst. 1993; 207–216.

37.

Schendel

D.J.

, Gansbacher

Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment. Cancer Res. 1993; 53: 4020–4025.

38.

Brunda

M.J.

, Luistro

, Warrier

Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med. 1993; 178: 1223–1230.